Sight Sciences Executive Stock Sales Disclosed via SEC Filing
2 reports, 1 independent
Updated Oct 8
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sight Sciences, Inc. disclosed executive stock sales through a legal filing with the SEC. The company's EVP, Brenton Taylor, sold 2,988 shares of Sight Sciences on October 2nd. The average selling price was $8.85 per share, totaling $26,443.80. Following the transaction, Taylor remained an owner of 261,990 shares.
From tickerreport.com
Why it matters
The disclosure concerns the sale of company stock by a senior executive. This information is made public through required filings with the SEC. The company also receives analyst ratings and coverage from Citigroup.
From tickerreport.com
Who's involved
- SIGHT SCIENCES, INC.Company subject to SEC disclosure requirements regarding executive stock sales.
- CitigroupProvides analyst ratings and coverage on Sight Sciences, Inc. stock.
- SECRegulatory body receiving required financial disclosures from publicly traded companies.
Keep exploring
The entities involved
-
SIGHT SCIENCES, INC.
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
-
SEC
Slovak company
Related events
- American Healthcare REIT, Inc. disclosed executive stock sales via a legal filing with the SEC on June 6, 2026.
- Arcutis Biotherapeutics, Inc. disclosed an executive stock sale via a filing with the SEC on November 11, 2026.
- Analyst ratings disclosed via SEC filing involving Morgan Stanley, Royal Bank of Canada, and the SEC.
- Reddit Inc. filed disclosures regarding executive stock sales with the SEC on July 6, 2026.
- Citigroup and Benchmark issued buy ratings for Strategy shares, while MarketBeat reported the consensus rating for the stock.